As ASIs are the backbone systemic treatment in metastatic prostate cancer, and AR gene amplification is a potential resistance mechanism, we hypothesized that depleted AR locus RCFS (enriched for ecDNA) would portend a decreased benefit from treatment with ASIs. The gene discussed is AR; the disease is metastatic prostate carcinoma.